Search Results

Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, received CDMO Leadership Awards in all six categories - Capabilities, Compatibility, Expertise, Quality, Reliability, and Service for both the Overall and Big Pharma respondent groups.

Ajinomoto Bio-Pharma Services today announced leadership changes at the company’s site in San Diego, effective immediately.

Ajinomoto Bio-Pharma Services is pleased to announce that the United States Food and Drug Administration (FDA) has approved the company’s high potency vial line to manufacture a commercial product.

Ajinomoto Bio-Pharma Services is pleased to announce the development of a new enzyme for double strand oligonucleotide formation with high productivity.

As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as Eli Lilly offers expanded Zepbound options; and struggling gene therapy biotech bluebird bio goes private in an attempt to stay solvent.

Ajinomoto Co., Inc. and Forge Biologics, announced that they have entered into a definitive agreement by which Ajinomoto Co., will acquire Forge, a leading manufacturer of genetic medicines, in an all-cash deal for $620 million.

Ajinomoto Co., Inc. launched a new version of its StemFit™ iPSC expansion medium.

Acasti Pharma Inc. announced that the Company will be participating in the BIO International Convention taking place at the San Diego Convention Center from June 3-6, 2024.